Abstract
In a previous study we have shown that the interleukin-3 receptor alpha chain (IL-3Ralpha) is over expressed in about 45% of acute myeloid leukemias (AMLs) and this phenomenon was associated with high blast cell counts at diagnosis, high rate of cycling of leukemic blasts and with a worse prognosis. Here we have investigated the immunophenotypic features of 125 AML patients subdivided into three groups (IL-3R(high), IL-3R(middle) and IL-3R(low)) according to the level of IL-3Ralpha expression. AMLs over expressing the IL-3Ralpha represent a subgroup of AMLs with a peculiar immunophenotype mainly consisting in the elevated expression of CD34 and several receptor membrane tyrosine kinases, such as c-kit and flt3, and in a usually low expression of myeloid-associated antigens such as CD11b, CD14 and CD15. These findings suggest that IL-3Ralpha + + + AMLs are blocked at an early stage of differentiation and express at elevated levels several growth factor receptors. It is proposed that these findings may further help to understand the mechanisms involved in the development of high-risk acute leukemias.
References
Sep 28, 1990·Science·M GabbianelliC Peschle
Oct 6, 2000·Leukemia·C T JordanG L Phillips
May 15, 2001·European Journal of Haematology·M De WaeleI Van Riet
Aug 16, 2001·International Journal of Hematology·Zahra AmirghofranAzra Shamseddin
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·Y YuanD E Zhang
Dec 4, 2001·Nature Genetics·Scott A ArmstrongStanley J Korsmeyer
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louise M KellyD Gary Gilliland
Sep 28, 2002·Blood·Ugo TestaCesare Peschle
Nov 15, 2002·The New England Journal of Medicine·William C Hahn, Robert A Weinberg
Nov 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Monica L GuzmanCraig T Jordan
Dec 7, 2002·Blood·Yinghui GuanDonna E Hogge
Feb 4, 2003·Nature Reviews. Cancer·Daniel G Tenen
Feb 8, 2003·Current Opinion in Genetics & Development·James R Downing
Mar 21, 2003·Leukemia·R O CasasnovasM C Béné
Apr 12, 2003·Leukemia·M WetzlerM R Baer
Apr 30, 2003·Cytometry. Part B, Clinical Cytometry·G ValetUNKNOWN SHG-AML study group
Apr 30, 2003·Cytometry. Part B, Clinical Cytometry·R ReppUNKNOWN AML-SHG Study Group
Jun 17, 2003·Molecular and Cellular Biology·Vernon T PhanScott C Kogan
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Sep 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emmanuelle PasseguéIrving L Weissman
Citations
Jun 29, 2012·Protein Engineering, Design & Selection : PEDS·Shu-Ru KuoJen-Sing Liu
Feb 26, 2008·Leukemia & Lymphoma·Arthur FrankelDonna Hogge
Jun 12, 2010·IUBMB Life·Angel F LopezMichael W Parker
Dec 11, 2013·British Journal of Haematology·Robin E GasiorowskiDerek N J Hart
Jul 3, 2009·Cell Stem Cell·Liqing JinRichard B Lock
Feb 19, 2011·Blood·Wei DuQishen Pang
Aug 30, 2016·The Journal of Clinical Investigation·Marco RuellaSaar Gill
Sep 27, 2014·World Journal of Stem Cells·Jianbiao Zhou, Wee-Joo Chng
Dec 19, 2017·Leukemia & Lymphoma·Tomohiro YabushitaTakayuki Ishikawa
Mar 19, 2020·Leukemia & Lymphoma·Fabio GuoloRoberto Massimo Lemoli
Feb 22, 2011·British Journal of Haematology·Roberta RiccioniUgo Testa
Jun 4, 2017·Cancer Discovery·Marco RuellaSaar Gill